| Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526) |
|---|
| 08/21/2003 | WO2002077210A3 Methods to culture circovirus |
| 08/21/2003 | WO2002074810A3 Isolated human ion channel proteins, nucleic acid molecules encoding human ion channel proteins, and uses thereof |
| 08/21/2003 | WO2002072140A3 Mhc-i-restricted presentation of hiv-1 virion antigens without viral replication. application to the stimulation of ctl and vaccination in vivo; analysis of vaccinating composition in vitro |
| 08/21/2003 | WO2002070727A3 Polynucleotide encoding a novel human potassium channel beta-subunit, k+betam6, expressed highly in the small intestine |
| 08/21/2003 | WO2002070695A3 Tumor associated proteins |
| 08/21/2003 | WO2002068650A3 Modified and stabilized gdf propeptides and uses thereof |
| 08/21/2003 | WO2002068473A8 Biosensor for detecting chemical agents |
| 08/21/2003 | WO2002064776A3 Signal transduction proteins 15b3, 15b3-1 and 15b3-2, and related dna sequences |
| 08/21/2003 | WO2002064748A3 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
| 08/21/2003 | WO2002064731B1 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines |
| 08/21/2003 | WO2002062999A3 Proteins and nucleic acids encoding same |
| 08/21/2003 | WO2002062844A3 Long lasting growth hormone releasing factor derivatives |
| 08/21/2003 | WO2002061102A3 Control of gene expression in plants |
| 08/21/2003 | WO2002060467A3 Compositions and methods for improving kidney function |
| 08/21/2003 | WO2002057452A3 Human proteins, polynucleotides encoding them and methods of using the same |
| 08/21/2003 | WO2002056022A3 Diagnostics, drug screening and treatment for cancer |
| 08/21/2003 | WO2002055554A3 Antimicrobial peptides and derived metapeptides |
| 08/21/2003 | WO2002051977A3 orfE-ZipA INTERACTION AND USES THEREOF |
| 08/21/2003 | WO2002050545A3 Compositions and methods involving staphylococcus aureus protein staau-r9 |
| 08/21/2003 | WO2002048175A3 Mhc class i associated peptides for prevention and treatment of tuberculosis |
| 08/21/2003 | WO2002047613A3 Immunogenic cancer peptides and uses thereof |
| 08/21/2003 | WO2002046416A3 Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| 08/21/2003 | WO2002046224A3 Compositions and methods relating to lung specific genes and proteins |
| 08/21/2003 | WO2002044209A3 Cytonkine receptor zcytor19 |
| 08/21/2003 | WO2002042467A8 Aspergillus fumigatus profilin |
| 08/21/2003 | WO2002040535A3 Compositions and methods relating to ovary specific genes and proteins |
| 08/21/2003 | WO2002036615A3 Methods for producing and improving therapeutic potency of binding polypeptides |
| 08/21/2003 | WO2002036611A3 Immunomodulatory peptides derived from heat shock proteins and uses thereof |
| 08/21/2003 | WO2002034880A3 Cadherin peptides for drug delivery and inhibition of tumor metastasis/invasion |
| 08/21/2003 | WO2002032925A3 Protein scaffolds for antibody mimics and other binding proteins |
| 08/21/2003 | WO2002029083A3 Industrial-scale serum-free production of recombinant proteins in mammalian cells |
| 08/21/2003 | WO2002029041A3 32146 and 57259, novel human transporters and uses thereof |
| 08/21/2003 | WO2002029001A3 Novel lysophosphatidic acid receptor agonists and antagonists |
| 08/21/2003 | WO2002020722A9 Methods and compositions for in vitro targeting |
| 08/21/2003 | WO2002020047A9 Chlamydial peptides and their mimics in demyelinating disease |
| 08/21/2003 | WO2002012284A3 Iron regulating protein-2 (irp-2) as a diagnostic for neurodegenerative disease |
| 08/21/2003 | WO2002010392A9 Mammalian dna binding membrane-associated protein-encoding gene and uses |
| 08/21/2003 | WO2002006445A3 Transgenic mice containing targeted gene disruptions |
| 08/21/2003 | WO2002006344A3 Rtvp based compositions and methods for the treatment of prostate cancer |
| 08/21/2003 | WO2002000717A3 Novel co-stimulatory molecules |
| 08/21/2003 | WO2001085792A3 Mu-1, member of the cytokine receptor family |
| 08/21/2003 | WO2001079479A3 Methods for selective targeting |
| 08/21/2003 | WO2001077365A3 Antimicrobial methods and materials |
| 08/21/2003 | WO2001060162A9 Cationic, amphipathic beta-sheet peptides and uses thereof |
| 08/21/2003 | US20030159185 Replication protein A and use |
| 08/21/2003 | US20030159183 Heterologous gene expression in plants |
| 08/21/2003 | US20030159182 Production of therapeutic proteins in transgenic cereal crops |
| 08/21/2003 | US20030159179 Genetic engineered transgenic plant; controlling,germination |
| 08/21/2003 | US20030159174 Genetic engineered plants |
| 08/21/2003 | US20030159171 Novel plant genes and uses thereof |
| 08/21/2003 | US20030159166 Collecting antibodies from immunized mouse |
| 08/21/2003 | US20030159162 Methods of using transporter-like molecules to treat pain and pain-related disorders |
| 08/21/2003 | US20030159159 Human nerve growth factor exon 1 and exon 3 promoters |
| 08/21/2003 | US20030158602 Contacting a cell containing a NELL-1 gene with a test agent; and detecting a change in the expression level of Nell-1 gene as compared to the expression of the NELL-1 gene in a cell that is not contacted with test agent |
| 08/21/2003 | US20030158402 Stimulant immunology response; prevent infections |
| 08/21/2003 | US20030158401 DNA encoding orphan SNORF13c receptor |
| 08/21/2003 | US20030158400 Antiinflammatory agents; autoimmune disease; rheumatic diseases; genetic engineered cells |
| 08/21/2003 | US20030158399 Compositions and methods for the treatment and diagnosis of immune disorders |
| 08/21/2003 | US20030158398 Central nervous system disorders; psychological disorders |
| 08/21/2003 | US20030158396 Identification of polynucleotides encoding novel helicobacter polypeptides in the helicobacter genome |
| 08/21/2003 | US20030158392 IP-10/Mig receptor designated CXCR3, antibodies, nucleic acids, and methods of use therefor |
| 08/21/2003 | US20030158391 Anitbodies and method for producing same, the use thereof and immunisation cocktails, immunoassays-sets and peptides |
| 08/21/2003 | US20030158388 MAGE-10 encoding cDNA, the tumor rejection antigen precursor MAGE-10, antibodies specific to the molecule, and uses thereof |
| 08/21/2003 | US20030158387 Processed human chemokines PHC-1 and PHC-2 |
| 08/21/2003 | US20030158386 Genetic engineered culture product; binding to antibodies |
| 08/21/2003 | US20030158384 Crystals and structures of members of the E. coli comA and yddB protein families (ComA) |
| 08/21/2003 | US20030158383 Ehrlichia chaffeensis 28 kDa outer membrane protein multigene family |
| 08/21/2003 | US20030158382 Bactericides; viricides |
| 08/21/2003 | US20030158381 Novel insulin/igf/relaxin family polypeptides and dnas thereof |
| 08/21/2003 | US20030158380 Immunology diagnosis analyzing; using computer |
| 08/21/2003 | US20030158379 A DNA molecules encoding the proteins, used in the treatment of bone, connective tissue, tendon, ligament, wound healing and defects to tissues, animal growth factors, cell differentiation of embryonic and stem cells |
| 08/21/2003 | US20030158378 Polypeptides; genetic engineering |
| 08/21/2003 | US20030158377 Forming libraries; immunosuppressant, antitumor agents |
| 08/21/2003 | US20030158376 Relaxin-like factor and methods and uses thereof |
| 08/21/2003 | US20030158375 Neutrophil stimulant; granulocyte colony stimulating factor; genetic engineering |
| 08/21/2003 | US20030158333 Thioester-terminated water soluble polymers and method of modifying the N-terminus of a polypeptide therewith |
| 08/21/2003 | US20030158142 For screening for compounds which affects apoptosis |
| 08/21/2003 | US20030158138 Nucleic acid construct encoding a processing component derived from the N-terminal region of the hepatitis virus ORF2, and an antigenic polypeptide |
| 08/21/2003 | US20030158135 Derived from staphylococcal genes; use of the polynucleotides as oligonucleotide primers or probes for detecting Staphylococcal strains that are resistant to streptogramin A or streptogramin B and related compounds in biological sample |
| 08/21/2003 | US20030158134 Use of HIV Tat protein or polynucleotide, HIV Nef protein or polynucleotide, HIV Tat protein or polynucleotide linked to HIV Nef protein or polynucleotide and HIV gpl20 protein or polynucleotide in manufacture of vaccine against hiv |
| 08/21/2003 | US20030158132 Method for enhancing bone density or formation |
| 08/21/2003 | US20030158131 DNA vectors containing mutated HIV proviruses |
| 08/21/2003 | US20030158130 Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
| 08/21/2003 | US20030158127 Aromatic sulfenates for type I phototherapy |
| 08/21/2003 | US20030158123 Purified material having size and growth inhibitory effects on cells and tissues |
| 08/21/2003 | US20030158115 Prevents adhesion of specific crystals to the surface of kidney cells and is used in an assay system to rapidly measure relative amounts of crystal adhesion to cells |
| 08/21/2003 | US20030158113 Administering to individual a therapeutically effective amount of osteopontin or a functional fragment |
| 08/21/2003 | US20030158111 Contacting animal's mouth tissue with peptide |
| 08/21/2003 | US20030158110 Vasoactive intestinal peptide analogs |
| 08/21/2003 | US20030158109 As markers for distinguishing between tumors which will or have metastasized and those which are less likely to metastasize |
| 08/21/2003 | US20030158108 For use as immuno-suppressive drugs; for therapy of pathologies that involve a dysfunction of calcium channels |
| 08/21/2003 | US20030158105 Determining polypeptide sequence of at least one Bcr-Abl polypeptide expressed by the human cancer cell and comparing the polypeptide sequence of the Bcr-Abl polypeptide expressed by the human cancer cell to the Bcr-Abl polypeptide sequence |
| 08/21/2003 | US20030158104 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 08/21/2003 | US20030158102 ICOS mutants |
| 08/21/2003 | US20030158101 Glucagon-like peptide-2 and its therapeutic use |
| 08/21/2003 | US20030158100 For use in therapy |
| 08/21/2003 | US20030158099 Cancer therapy |
| 08/21/2003 | US20030158098 Colon specific gene and protein |
| 08/21/2003 | US20030158096 Novel molecule |
| 08/21/2003 | US20030158092 For therapy of glycoprotein aberration disorders (e.g., cystic fibrosis), including gene therapy |